Healthcare Industry News: LifeCell
News Release - June 1, 2011
Abiomed Announces Appointment of Paul G. Thomas to Board of DirectorsDANVERS, Mass.--(Healthcare Sales & Marketing Network)-- Abiomed, Inc. (NASDAQ:ABMD ), a leading provider of breakthrough heart support technologies, today announced the appointment of Paul G. Thomas to the Company’s Board of Directors.
Currently, Mr. Thomas is Chief Executive Officer and Founder of Roka Bioscience, a company focused on the development and commercialization of molecular assays and is a Director of Orthovita, Inc. (NASDAQ:VITA ). Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation until it was acquired by KCI in 2008 and also held various senior positions during his tenure of 15 years with Ohmeda. Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business, completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science and received his B.S. degree in Chemistry from St. Michael’s College in Vermont.
"We are extremely pleased and fortunate to have Paul join the Abiomed Board of Directors,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “Paul’s previous experience and record of achievement at LifeCell Corporation is well recognized. His guidance will be invaluable as we execute our plan toward driving further adoption of the Impella heart recovery platform.”
"This is an exciting time for Abiomed and I am looking forward to working with the team," said Mr. Thomas.
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.